News | February 19, 2010

Rapid MRI, CT Growth Seen in National Health Technology Report

February 19, 2010 – The use of medical technology in the United States increased dramatically between 1996 and 2006, according to “Health, United States, 2009,” the federal government’s 33rd annual report to the president and Congress on the health of all Americans.

The report was prepared by the Centers for Disease Control and Prevention’s National Center for Health Statistics from data gathered by state and federal health agencies and through ongoing national surveys.

This year's edition features a special section on medical technology, and finds that the rate of magnetic resonance imaging (MRI), and computed and positron emission tomography (CT and PET) scans ordered or provided, tripled between 1996 and 2007.

Highlights of the special section include:

• The rate of adults ages 45 and older discharged from the hospital after receiving at least one knee replacement procedure increased 70 percent from 1996 to 2006 (26.5 per 10,000 population in 1996 to 45.2 per 10,000 in 2006).

• From 1988–1994 to 2003–2006, use of anti-diabetic drugs among adults ages 45 years and older increased about 50 percent, and the use of statin drugs to lower cholesterol among this age group increased almost tenfold.

• The number of new organ transplantations per 1 million people increased 31 percent for kidney transplants (43.7 per 1 million in 1997 vs. 57.2 in 2006) and 42 percent for liver transplants between 1997 and 2006 (15.6 per 1 million in 1997 vs. 22.2 in 2006).

The full report contains 150 data tables in addition to the special feature on medical technology. The tables cover the spectrum of health topics, serving as a comprehensive snapshot of the nation's health.

Life expectancy at birth increased more for the black than for the white population between 1990 and 2007, thereby narrowing the gap in life expectancy between these two racial groups. Overall U.S. life expectancy in 2007 was 77.9 years.

In 2007, 20 percent of U.S. adults were current cigarette smokers, a slight decrease from 21 percent in the previous three years. Men were more likely to be current cigarette smokers than women (22 percent vs. 17 percent).

In 2005–2006, 30 percent of adults often or almost always had trouble sleeping in the past month.

In 2007, 20 percent of adults 18 years and over had at least one emergency department visit in the past year, and 7 percent had two or more visits.

The percentage of the population taking at least one prescription drug during the previous month increased from 38 percent in 1988–1994 to 47 percent in 2003–2006, and the percentage taking three or more prescription drugs increased from 11 percent to 21 percent.

The full report is available at www.cdc.gov/nchs/hus.htm

Related Content

ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging

A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging. Graphic courtesy of the Department of Nuclear Medicine, Royal North Shore Hospital, Sydney

News | Prostate Cancer | June 15, 2017
An estimated one in seven American men will be affected by prostate cancer in their lifetime. Prostate-specific...
Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer

IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.

Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.

This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.

Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B.  Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.

News | Prostate Cancer | June 15, 2017
In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may...
Axial fused 89Zr-5B1 antibody PET/CT image demonstrates focus of uptake in the liver (arrow). Focus of uptake correlates with increased liver metastasis seen on diagnostic CT (red arrow) performed 2 weeks prior

Axial fused 89Zr-5B1 antibody PET/CT image demonstrates focus of uptake in the liver (arrow). Focus of uptake correlates with increased liver metastasis seen on diagnostic CT (red arrow) performed 2 weeks prior. Image courtesy of Christian Lohrmann, Jason Lewis, Wolfgang Weber, Memorial Sloan Kettering Cancer Center; MabVax Therapeutics

News | PET-CT | June 14, 2017
Pancreatic cancer is associated with bleak five-year survival rates and limited treatment options, but new research is...
PET/CT
News | PET-CT | June 12, 2017
Philips announced that it will be showcasing molecular imaging solutions highlighting Philips’ commitment to innovation...
News | PET-CT | June 12, 2017
Siemens Healthineers has announced that the Food and Drug Administration (FDA) has cleared Biograph Horizon Flow...
Toshiba Medical launches its new Celesteion PUREViSION Edition PET/CT system to help diagnose and treat oncology patients

Toshiba Medical launches its new Celesteion PUREViSION Edition PET/CT system to help diagnose and treat oncology patients.

News | PET-CT | June 09, 2017
Oncologists have access to advanced imaging technologies for excellent cancer patient care with the new Celesteion...
News | SPECT-CT | June 08, 2017
Siemens Healthineers debuts Symbia Intevo Bold at the 2017 annual meeting of the Society of Nuclear Medicine &...
Overlay Init